Method for the production of a formulation of a hypericin salt
Photodynamic therapy of tumors such as bladder tumors includes photosensitizing with a photosensitizer that is a complex or a compound of hypericin and a polymeric complexing agent. The photosensitizer is formed from an alkali salt of hypericin and the polymeric complexing agent. The alkali salt of hypericin is a sodium salt or a potassium salt. The complexing agent is a polyethylene glycol or a poly-N-vinyl amide.
1. A method for the production of a formulation of a hypericin salt, comprising:
bonding or complexing the hypericin salt to a polyethylene glycol, a poly-N-vinyl amide, or polyvinylpyrrolidone (PVP);
adding a buffer system comprising a phosphate buffer or a citric acid buffer to obtain a concentration of 0.0225 mg hypericin/g solution; and
lyophilizing the solution to obtain lyophilizate to yield 0.225 mg hypericin.
2. A method for the production of a formulation of a hypericin salt, comprising:
bonding or complexing the hypericin salt to a polyethylene glycol, a poly-N-vinyl amide, or polyvinylpyrrolidone (PVP);
adding a buffer system comprising a phosphate buffer or a citric acid buffer to obtain a concentration of 0.0225 mg hypericin/g solution; and
lyophilizing the solution to obtain lyophilizate to yield 0.225 mg hypericin,
wherein the complexing is performed in aqueous solution.
3. The method according to claim 2 , wherein the aqueous solution is decanted into injection flasks and freeze-dried.
4. The method according to claim 1 , wherein the formulation is prepared for intravenous, intracavity, inhalative, oral, intraperitoneal and topical administration, in hydrophilic or hydrophobic vehicles, or in the form of a solution, a cream, a gel, an aerosol, emulsions or as a patch.
5. A method for the production of a formulation for photodynamic therapy, comprising:
bonding or complexing a hypericin salt to a polymeric complexing agent selected from the group consisting of a polyethylene glycol, a poly-N-vinyl amide, and polyvinylpyrrolidone (PVP), wherein
the formulation is a stable complex or a stable compound of a sodium or potassium salt of hypericin, wherein the photosensitizer is obtained from a lyophilisate obtained from a solution of the sodium or potassium salt of hypericin, containing 0.0225 mg hypericin/g solution, the polymeric complexing agent and a buffer system comprising a phosphate buffer or a citric acid buffer, and
the formulation has been lyophilized to obtain lyophilizate to yield 0.225 mg hypericin in each resulting obtained photosensitizer.
6. The method according to claim 5 , wherein the formulation is prepared for intravenous, intracavity, inhalative, oral, intraperitoneal and topical administration, in hydrophilic or hydrophobic vehicles, or in the form of a solution, a cream, a gel, an aerosol, emulsions or as a patch.
7. A method for the production of a formulation for photodynamic therapy, comprising:
bonding or complexing a hypericin salt to a polymeric complexing agent selected from the group consisting of a polyethylene glycol, a poly-N-vinyl amide, and polyvinylpyrrolidone (PVP), wherein
the formulation is a stable complex or a stable compound of a sodium or potassium salt of hypericin, wherein the photosensitizer is obtained from a lyophilisate obtained from a solution of the sodium or potassium salt of hypericin, containing 0.0225 mg hypericin/g solution, the polymeric complexing agent and a buffer system comprising a phosphate buffer or a citric acid buffer, and
the formulation has been lyophilized to obtain lyophilizate to yield 0.225 mg hypericin in each resulting obtained photosensitizer,
wherein the complexing is performed in aqueous solution.
8. The method according to claim 7 , wherein the aqueous solution is decanted into injection flasks and freeze-dried.